Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alizyme reports cetilistat Phase III development plan
Following successful end of Phase II discussions, FDA has approved the company’s outline plan for the Phase III clinical development program of cetilistat. This development plan comprises three
Following successful end of Phase II discussions, FDA has approved the company’s outline plan for the Phase III clinical development program of cetilistat. This development plan comprises three
Invitrogen’s drug discovery products will be validated on selected Tecan microplate readers and instruments, starting with the Infinite series readers. Initial certifications will focus on Invitrogen’s assay systems
Proteomika has ordered novel, HuCAL-based, research antibodies against a broad range of target molecules in addition to the production of antigen material at AbD Serotec. The order ranks
Unidym brings to this partnership its leadership in carbon nanotube science, technology and production. PrimeGen will have access to Unidym’s extensive patent portfolio, services and industry standard Hipco
This substantial award will fund the work necessary to bring the company’s neuropathic pain treatment, SCP-123, from the laboratory to the clinic, including the preparation of the investigational
In this study, 20 previously untreated elderly patients were treated with a novel combination of six cycles of CHOP chemotherapy followed by Zevalin given six to ten weeks
This positive opinion from the CHMP needs to be ratified by the European Commission in the coming months before final approval. The new 300mg tablet will facilitate the
The company said that Health Canada’s target is to complete review within 300 days for 90% of submissions. Vivian Liu, president and CEO of NexMed, said: “We are
The agreement includes the initial development and supply of quality control standards for 10 molecular targets that will be used in the development of Beckman Coulter’s molecular UniCel
Duramed’s Seasonique patent is due to expire on January 30, 2024. In addition to the patent, the company also has three-year new product exclusivity for its Seasonique product